# TABLE OF CONTENTS

Message from Brent Saunders, Chairman, President & CEO  

**Introduction**  
Sustainability Program and Reporting Scope, Limitations and Processes  
Sustainability Structure and Reporting Relationships  
Allergan and the Precautionary Principle  
2011–2015 Allergan Strategic Performance Goals & Results  
Allergan’s 2020 Goals  
EHS Regulatory Compliance  
Management Systems  
Risk Assessment Process  
Corrective Action Process  
Allergan’s EHS Audit Program  
Sustainable Supply Chains  
Innovation  
Impacts, Materiality, Risks and Opportunities  
Stakeholder Engagement and Collaborations  
Managing Climate Change  
Waste Management and Recycling  
Water Management  
Waste Water Discharge Indicators  
Use of Mercurial Preservatives  
Allergan EHS Product Design  
Air Emission Discharge Indicators  
Keeping Employees and Contractors Safe  
Diversity, Training, Development and Recognition  
Bioethics  
Corporate Statement on Animal Testing  
Philanthropy and Citizenship  
Access to Medicines – Our Social Contract  
Addressing Patient Needs  
Cost Burden and Health Outcomes  
Biodiversity  
Recognizing Excellence  
Conclusion  
Sustainability Performance Summary Table  
Report on the Verification of GHG Emissions  
Appendix
Allergan plc is a bold, global pharmaceutical company focused on innovation and bringing to market treatments that improve lives, every day. This focus is driven by deep engagement with healthcare providers – our customers – and understanding the innovation they need for their patients.

We are mindful of our impact on the world around us. Allergan has a deep commitment to the health, safety, and well-being of the people who put their trust in our products and the global communities where we operate. We are committed to ensuring our contribution to science reflects our commitment to safe, healthful workplaces, strong communities and responsible, ethical business practices in everything we do – research and development, manufacturing and distribution.

As a company, we’ve set an ambitious goal to further reduce our sustainability impact 20% by 2020 (our 20/20 Challenge). In 2015, while completing a significant business integration, we continued to improve our sustainability performance. We were recognized as Sustained Excellence Energy Star Partner of the Year by the US Environmental Protection Agency and several of our facilities were recognized by external stakeholders for our sustainability efforts. Additional highlights are included in this report.

Allergan remains focused on sustainable business practices including:
- Offering needed products that have environmental health and safety design considerations,
- Managing our environmental impact by improving energy, waste, and water efficiency,
- Providing a safe and healthy workplace for our employees,
- Working with our supply chains to improve corporate responsibility performance, and
- Executing on the principals of our Social Contract with our patients.

More information about areas of our commitment is provided throughout the Responsibility section of our website, our Annual Report, and Form 10-K.

Allergan is committed to sustainable business values. We work to keep these values in mind in all aspects of our business so we maintain the excellent reputation we enjoy with our global stakeholders.
2015 proved to be another successful year for Allergan’s sustainability program. Allergan’s specific performance against the 2015 goals is described in the Strategic Performance Goals & Results. Our goals were achieved while the organization completed the integration of Allergan Inc, and Actavis, plc.

In summary, comparing 2015 with 2014, Allergan achieved the following:\(^1\):

- The occupational injury and illness frequency rate improved by over 35% to 0.49.\(^2\)
- Recycling reached a rate of more than 80% of total nonhazardous waste generated.
- Total energy consumption increased by 1% for current sites but this equates to a decrease of 7% year over year if normalized for increased production as measured by sales revenue.
- Total Greenhouse Gas emissions increased by 4% for current sites, but likewise, this equates to a decrease of 4% year over year if normalized for increased sales.
- Total water consumption decreased by 4% for current sites but this equates to a decrease of 11% year over year if normalized for increased sales.

Reporting includes economic, governance and social parameters as well as environmental health and safety parameters. Tactical approaches to meeting the desired goals are included. Allergan positions and policies on current sustainability issues are presented. These include climate change, pharmaceuticals in the environment, water curtailment, packaging management, biodiversity, bioethics, energy independence, life cycle and carbon footprint approaches, green chemistry, ethnic, age and gender diversity, governance and ethics, supply chain enhancements, and community support. Data on our energy consumption and greenhouse gas emissions is externally verified by a third party in conformance with ISO 14064.

---

2. The occupational injury and illness rate is determined by multiplying the total number of injury and illness incidents by 200,000 hours and dividing this by the total number of hours worked, i.e., an incident rate of 1.00 would be equivalent to 1 incident per 200,000 hours worked.
SUSTAINABILITY PROGRAM AND REPORTING SCOPE, LIMITATIONS AND PROCESSES

Scope
Allergan’s sustainability program involves the business/economic, social and environmental aspects as defined by the Global Reporting Initiative (GRI) and Allergan’s internal assessment of various risks by the company as well as to the company. The programs encompass all aspects of Allergan operations including research and development, production, marketing, sales, customer support, regulatory management, regional and country-specific management, joint venture and third-party venture management, supplier management, and product stewardship through the entire supply chain. Most of the quantitative data presented in our report represents our R&D and manufacturing organizations.

Changes in scope occur when Allergan acquires new products, processes or businesses which have occurred several times in past years. The scope also changes when products are discontinued or divested and when facilities or businesses are consolidated or divested. Programs, performance and reporting are adjusted to account for these changes as they occur. Allergan has enlisted Ecodesk to help gather supply chain greenhouse gas emission information based on purchasing data, in order to develop a carbon footprint for Allergan’s supply chain. The supply chain footprint is included in the summary table and discussion sections in this report.

Limitations
Allergan is including owned or leased locations worldwide in its responses and summaries along with supply chain data for specified programs. Allergan is including both third-party validated and certified data and information as well as internal data which has not been third-party validated or certified. The Sustainability Performance Table is limited to data from our Research & Development and Manufacturing operations unless otherwise stated. Allergan has included data and information that Allergan feels, based on internal and external risk assessments, are not necessarily significant risks, but are required or recommended by various third-parties for reporting and analysis such as RobecoSAM, Dow Jones Sustainability Indexes (DJSI), Ethical Investment Research Services, Ltd. (EIRIS), FTSE4Good, Global Reporting Initiative (GRI), UN Global Compact, and Carbon Disclosure Project (CDP). Data not considered significant by the various regulatory entities or relevant Non-Governmental Organizations (NGOs) are not included. As with changes in scope, limitations are adjusted as the scope changes.

Previously reported data for 2014 have been adjusted to include Actavis, plc operations that have remained with Allergan, plc. Consistent with our financial reporting, we have excluded from this report data from operations that were discontinued and/or divested in 2016.

Data Capture and Verification
Economic data is captured through various systems and the methodology for capture and management of these data is well defined and third-party verified by audit. Social and environmental data are captured through various methods and managed through various systems such as ALL-EHS, SAP and SharePoint. ALL-EHS is Allergan’s launched sustainability data management system. The system served as the source for all data charts included in this report. The data are verified internally as part of the various audit programs. ERM Certification & Verification Services (ERM CVS) was commissioned by Allergan to verify our 2015 consolidated global GHG inventory data as reported in Section C8.2 and CC8.3 of our CDP disclosure. The verification time period was January 1, 2015–December 31, 2015 and covered emissions of CO2, N20, CH4, SF6, PFCs, and HFCs from direct, Scope 1 sources (fossil fuel combustion, refrigerants, processes, company-owned vehicles) and indirect, Scope 2 sources (electricity) for Allergan’s operations. A verification statement from ERM CVS along with a list of facilities included in Allergan’s emissions profile can be found in Appendix A. The data included in our Performance Summary table is related to our manufacturing /R&D operations and was not verified by ERM CVS.

Reporting Cycles
Generally, reporting of environmental, health and safety data is conducted internally on a monthly basis with annual summary reports generated for the calendar year. Allergan operates on a calendar year basis.

Report Content Process
Allergan generates various reports for economic, social and environmental purposes. These reports are defined as stated above by using internal, regulatory and best practices recommended or required by third-party groups.

Report Contact
Direct all inquiries to corporate.communications@allergan.com
SUSTAINABILITY STRUCTURE AND REPORTING RELATIONSHIPS

Allergan EHS and Sustainability Steering Committee
Allergan has established an Environmental, Health and Safety (EHS) Steering Committee with representatives from key business functions led by the Chief Operations Officer and including leadership in Operations, R&D, Legal, HR, Finance and EHS. This committee meets to set policy, direction, goals and metrics, and to evaluate performance against the goals and metrics established. Meetings generally are scheduled twice per year.

Sustainability Structure and Relationships
Allergan’s SVP of EHS and Engineering reports to the Executive Committee through the SVP Global Operations. The VP EHS (reporting directly to the SVP EHS and Engineering) is responsible, in concert with the Director of Sustainability and Product Stewardship, for coordinating, collecting and developing the Sustainability Report. The VP EHS also manages the strategic and daily coordination of EHS and Sustainability activities for Allergan.

Each manufacturing and R&D facility has an EHS staff that manages sustainability initiatives as well as daily EHS activities. The commercial offices sustainability initiatives and activities are managed by local human resources and finance representatives.

Economic and social sustainability initiatives and activities are managed by several groups depending on their roles and responsibilities within Allergan.

ALLERGAN AND THE PRECAUTIONARY PRINCIPLE

Allergan has always practiced the Precautionary Principle with regard to its products and operations. The inherent nature of researching and developing drug products for human use demonstrates the Precautionary Principle in action. Allergan considers the impacts of actions undertaken through a rigorous risk assessment process, with multiple gates through which the company proceeds when the risks are determined to be acceptable to Allergan and the various stakeholders in the process including patients, physicians, employees, government officials, investors, and others.
### 2011–2015 ALLERGAN STRATEGIC PERFORMANCE GOALS & RESULTS

<table>
<thead>
<tr>
<th>OBJECTIVE</th>
<th>GOAL</th>
<th>2010 vs 2015 RESULTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Injuries and Illness</td>
<td>Incident rate below 0.80</td>
<td>✓ 0.49</td>
</tr>
<tr>
<td>Recycling</td>
<td>Recycle &gt; 75% of waste</td>
<td>✓ 83% Recycling rate</td>
</tr>
<tr>
<td>Waste Reduction</td>
<td>Reduce by 15% compared to 2010</td>
<td>✓ 77% reduction in waste intensity (metric tonnes/sales). 29% reduction in absolute landfill waste. This was a significant reduction as it includes Actavis plc operations not included in 2010 baseline</td>
</tr>
<tr>
<td>Energy Reduction</td>
<td>Reduce by 15% compared to 2010</td>
<td>✓ 55% reduction in energy intensity (GJ/sales). 39% increase in absolute energy due to addition of Actavis plc operations not included in 2010 baseline</td>
</tr>
<tr>
<td>Water Reduction</td>
<td>Reduce by 15% compared to 2010</td>
<td>✓ 63% reduction in water intensity (m3/sales). 14% increase in absolute water consumption due to addition of Actavis plc operations not included in 2010 baseline</td>
</tr>
<tr>
<td>GHG Emissions Reduction</td>
<td>Reduce by 15% compared to 2010</td>
<td>✓ 55% reduction in greenhouse gas emissions intensity (metric tonnes/sales). 36% increase in absolute greenhouse gas emissions due to addition of Actavis plc operations not included in 2010 baseline</td>
</tr>
<tr>
<td>Green Energy Electricity is renewable</td>
<td>&gt;15% of Purchased</td>
<td>✓ 20% of purchased electricity is from renewable sources</td>
</tr>
</tbody>
</table>

### ALLERGAN’S 2020 GOALS

In our pursuit of continual improvement we have established 2020 goals to further reduce our sustainability impact compared to our 2015 baseline:

- Reduce our employee injury rate by 10% every year from 2016 to 2020 (as defined by ASTM E2920 – 14: Standard Guide for Recording Occupational Injuries and Illnesses).
- Reduce energy and fuel consumption by 20% compared to 2015.
- Reduce greenhouse gas emissions by 20% compared to 2015 (aligned with the Science Based Targets approach as endorsed by CDP, WWF, WRI and the UN Global Compact).
- Reduce water consumption in operations located in extreme water scarcity risk regions by 20% compared to 2015.
- Reduce total waste generated by 20% compared to 2015.
- Eliminate waste to landfill from manufacturing operations.

### EHS REGULATORY COMPLIANCE

Allergan did not receive any penalties or fines in 2015. Our San Jose site did receive a notice of violation for pH excursion in their effluent. The company is viewed by local regulators as a model business from an EHS perspective. As an example, Allergan has served as a demonstration case at its Waco, Texas manufacturing location for US EPA auditors auditing the City of Waco environmental permit compliance program.
MANAGEMENT SYSTEMS

Allergan has developed an internal Environmental, Health and Safety Management System (EHSMS). We consider our system to be in conformance with ISO 14001/OHSAS 18001. Our management system includes an overall Environmental, Health and Safety policy and defines key requirements that must be in place across the organization to reduce our impact. These requirements address management issues such as responsibility, goals and objectives, performance monitoring, training, corrective/preventive action (CAPA) tracking, auditing, risk assessment, and management review. They also address various technical areas such as incident management, emergency response, process safety, physical hazards, occupational health, environmental management, and transportation. Guidance is provided to operating locations to ensure adequate implementation of the requirements.

RISK ASSESSMENT PROCESS

Proactively identifying potential workplace environmental, health, and safety risks is a critical part of ensuring we provide a safe workplace for our employees, and reduce our environmental risks. Our risk assessment process includes identification of high level risks using a risk map as well identifying work area, and task specific risks. Allergan’s risk assessment process, facilitated by a web based tool, is completed by environmental, health and safety professionals in consultation with engineering, management, and work area employees. The risk assessment process begins with an identification of all tasks associated with a work activity, process, or the operation of equipment. After task identification, the EHS risks for each task are identified and evaluated based on frequency, likelihood of occurrence, and severity. Corrective actions are identified, and implemented to reduce the medium and high risks.

CORRECTIVE ACTION PROCESS

Allergan has established a robust process for identifying and correcting hazards. The process is facilitated with the use of our CAPA Tracking Program within our EHS Management Information System. The use of this system has allowed for higher accountability for completion of corrective actions identified from audits, inspections, near miss events, and other potential EHS non-conformances. This process has allowed for development of more effective preventive actions and has reduced the likelihood for reoccurrence of non-conformances.

<table>
<thead>
<tr>
<th></th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Risk Assessments</td>
<td>109</td>
<td>264</td>
<td>153</td>
<td>161</td>
<td>246</td>
</tr>
<tr>
<td>Corrective Actions/ Preventive Actions (audits, incidents, risk assessments)</td>
<td>133</td>
<td>542</td>
<td>693</td>
<td>653</td>
<td>1600</td>
</tr>
</tbody>
</table>
**ALLERGAN’S EHS AUDIT PROGRAM**

Allergan has a comprehensive program in place for conducting environmental, health and safety audits of our internal operations. The objective of the audit program is to identify EHS risks and potential compliance gaps and to identify best practices across our various locations and industry. Corrective and prevention action plans are developed for identified risks and tracked to closure. The audit process promotes vertical standardization from the corporate office to the worldwide network of plants as well as horizontal standardization among the various departments within the business.

Through the EHS audit program Allergan has been able to minimize the EHS risks at its facilities, and lower the risk of regulatory action (non-compliance) or community complaints against Allergan.

**SUSTAINABLE SUPPLY CHAINS**

**Sustainable Supply Chain Projects**

We understand that our sustainability impact not only includes Allergan’s operations but also the activities of our suppliers and other business partners. We have begun to prioritize the impact of our key suppliers by engaging them and requesting that they provide data concerning their water use and greenhouse emissions. We are working with EcoDesk to facilitate this process. Our plan is to partner with the suppliers that have the most impact on our footprint to identify significant reduction opportunities.

We also continue to actively participate in the Pharmaceutical Supply Chain Initiative (PSCI). This consortium of pharmaceutical companies is advancing comprehensive sustainability supply chain auditing. The audit protocols include social aspects such as human slavery and trafficking, child labor, ethics, compensation, benefits and other human rights, governance including ethics and human rights abuse management, and environmental management and performance. These audits will enhance our supplier review process and benefit our suppliers, our organization and our stakeholders.

**California Transparency in Supply Chains Act of 2010**

The California Transparency in Supply Chains Act of 2010 is intended to provide public information from manufacturers regarding the activities they engage in to monitor their supply chains to prevent human trafficking and slavery. These disclosures allow businesses and consumers to make more informed decisions regarding the products they choose to purchase and the companies with whom they choose to conduct business.

Allergan is committed to conducting business only with suppliers who adhere to the highest ethical standards and comply with laws and regulations applicable to their business. Allergan has undertaken actions to ensure that the services and materials provided to Allergan meet this commitment.

**Supplier Assessments and Qualification**

Prior to engagement of a supplier, Allergan evaluates the supplier through a risk-based assessment. Such assessments may include supplier questionnaires and audits of supplier facilities. Allergan expects all potential suppliers to comply with all federal, state and local rules and regulations and work to the highest ethical and quality standards.

**Supplier Performance Reviews**

Allergan is committed to continuous improvement in its supply chain. Allergan and its suppliers monitor business performance through periodic evaluation and review of defined performance targets and objectives.

**Supplier Audits**

Allergan also regularly audits key suppliers to confirm compliance with supplier performance and quality standards. Audits are performed by Allergan or third parties contracted by Allergan.
Supplier Agreements
Allergan has supply agreements, quality agreements and/or purchase order terms and conditions with all of its suppliers. These contracts include agreement to comply with all laws and regulations applicable to the supply of the service or material.

Employee Training and Compliance
All Allergan employees are required to comply with Allergan’s Code of Business Conduct and Ethics. All Allergan employees participate in annual training on the company’s Code to ensure understanding and compliance with the requirements of the Code. This training includes training on ethical decision making and upholding laws and regulations. In addition, Allergan maintains a compliance program that conducts regular audits of the requirements under the Code, investigates potential violations of the Code and takes disciplinary action when necessary.

INNOVATION
Allergan’s world-class research and development (R&D) program embodies our efforts to bring the best of medicine to life. Scientists and researchers work closely with medical specialists to transform novel compounds into new therapeutics that help improve quality of life.

Our commitment to R&D has been evident since the 1950’s, when we began pioneering new treatments to help preserve and protect eye health. Since then, our investment in R&D has progressively increased to a level that is considered best in class for the industry, and we have followed our products into new specialty areas. Our R&D programs today are focused in eye care, neurosciences, medical aesthetics, medical dermatology, gastroenterology, women’s health, anti-infectives and urological diseases. Currently, we are investigating a rich arsenal of potential new treatments for chronic migraine, Alzheimer’s disease, debilitating neurological conditions, gastrointestinal disorders, eye diseases, women’s health conditions and serious infections, among other conditions. Significant progress in these areas is expected to be made over the next decade - we look forward to playing a prominent role in driving this innovation forward.

Since Allergan’s founding, the ability to build bridges – with our customers and with each other – has been a cornerstone of our success. Allergan’s R&D culture reflects this, through Open Science, by identifying the best innovation from throughout the biopharma ecosystem, including academia, biotechnology companies, small pharmaceutical companies and venture-backed companies. Access to world-class technology combined with intellectual stimulation results in a dynamic environment where scientists are excited about the work they do and committed to pushing the boundaries of what is possible.

Our R&D organization is structured into integrated teams that focus on discovery for different drug targets. This unique architecture affords many benefits. Scientists normally confined to specific tracks have the opportunity to be involved in the full life-cycle of development, from
early-stage exploration to human clinical testing, for a much broader perspective. Additionally, meticulous research is streamlined with highly efficient project and information management, which can save years and millions of dollars from the overall cost of drug development.

In short, at Allergan, there is only one way in which we view science and innovation - to identify unsolved needs in health care and commit to finding solutions through a meaningful R&D investment that fuels future growth. This is our unwavering commitment.

IMPACTS, MATERIALITY, RISKS AND OPPORTUNITIES

Based on internal analysis of risk and opportunities, the following figure represents Allergan’s view of perceived importance of various sustainability areas to our stakeholders and potential opportunities to positively differentiate Allergan from our competitors. Allergan has aligned its strategic and annual objectives with the greatest perceived importance to our stakeholders’ combined with the greatest positive influence on our company. As reported in various sections of this report, Allergan continues to set a high bar for itself. Achieving these objectives also has the benefit of allowing Allergan to place resources against improving its sustainability footprint. Opportunities continue to present themselves in the areas of product safety, ethical practices, stakeholder and employee engagement, community interaction, and supply chain management. These areas have significant resources devoted to them and are being attained at a rapid rate.

STAKEHOLDER ENGAGEMENT AND COLLABORATIONS

Allergan’s view of stakeholders is very broad, encompassing patients, doctors, employees, shareholders, upstream and downstream supply chain partners, regulators, governments, communities and non-governmental organizations. Worldwide sustainability collaborations include various commitments with the UN Global Compact such as the CEO Water Mandate, Caring for Climate, and Anti-Bribery and Anti-Corruption Support. Allergan has shared best practices in water, energy and GHG management that it has instituted at its locations worldwide. We have participated in several committees in support of efforts to disseminate this information in collaboration with the UN Global Compact. Regulatory collaborations are extensive, including USEPA Energy Star. Allergan has again shared best practices from its operations with others and continues to support the Energy Star philosophy. Business customer collaborations include Walmart, Kaiser, Target and the French Hospital Systems, among others. These collaborations have allowed these customers to understand where Allergan is on the sustainability spectrum. Non-governmental organization (NGO) collaborations include United Way, Carbon Disclosure Project, Newsweek Green Business Rankings, RebecoSAM-DJSI investor index, EIRIS-FTSE4Good investor index, Maplecroft Climate Innovation Index, GRI G3 conformance and input into the reporting process and parameters among others. These have allowed Allergan to share and receive best practices as well as benchmark our programs against other best in class sustainable companies. Community collaborations include direct community support projects in Brazil, Costa Rica, Ireland, and the USA as well as indirect collaborations through the Allergan Foundation. We continue to evaluate our approach and performance in order to drive continuous sustainable improvement at Allergan.
MANAGING CLIMATE CHANGE

Allergan has had a long history of addressing climate change through development and implementation of energy conservation programs to reduce fuel and electricity consumption. Allergan plc and its legacy companies have also been involved in many initiatives to facilitate our programs including USEPA’s Climate Wise, EPA’s Energy Star program, EPA’s Green Light Program, the Carbon Disclosure Project, California’s Climate Action Registry program, and the Climate Registry Program. Our leadership in energy conservation has been recognized by, among others, the EPA Energy Star program. In 2015, we were recognized an Energy Star Partner of the Year – Sustained Excellence for the 5th year. Our Waco, TX, and Cincinnati, OH facilities were selected as Energy Star Plants. The award recognizes facilities ranking in the top 25 percent of pharmaceutical plant energy performance nationwide.

All our R&D and manufacturing facilities have site targets regarding energy consumption reductions and efficiency improvements. The Allergan vehicle fleets worldwide are reporting fuel consumption and have established auto selections in their fleets that are improving fuel efficiency. Allergan is collecting information from commercial offices and distribution centers (generally third-party operated).

The 2015 overall GHG emissions for Allergan manufacturing and R&D operations are presented in the following graph. Scope 1 GHG emissions refer to the direct GHG emissions resulting primarily from combustion processes. Scope 2 GHG emissions refer to GHG emissions resulting primarily from the consumption of purchased electricity. Allergan reduced GHG emissions intensity (normalized to sales) by 4% for its R&D and manufacturing operations in 2015 versus 2014. On a normalized to sales basis, the GHG emissions decreased by 37% in 2010 vs 2015. In 2015, due to the addition of five (5) legacy Actavis sites, our absolute GHG emissions increased by 39% vs 2010. Allergan has aggressively improved the energy efficiency of existing systems and designed energy efficiency into new projects.
Energy Management
Allergan set an aggressive goal to reduce energy consumption by 15% by 2015 using 2010 as the baseline year. We achieved a 39% reduction in energy intensity (GJ/sales) in 2015 compared to 2010. There were also significant increases in our production activities during this time. Comparing 2015 and 2014, our total energy consumption decreased by 7% year over year normalized to sales revenue.

We use tools such as Lean 6 Sigma, Kaizen events, metering and sub-metering, to identify energy reduction opportunities. In 2015, we enhanced our internal expertise by hiring a seasoned Director of Energy. We also established a capital fund dedicated for energy reduction projects. To share best practices around the organization and improve knowledge, we have established an energy team.

Supply Chain
During the past four years Allergan has begun an initiative to gain a better understanding of the greenhouse gas emissions of our external supply chain. In 2011, we contracted Trucost to model greenhouse gas and water emissions from our top 200 suppliers based on monies spent. In 2013, we continued our supplier engagement process by requesting greenhouse gas emissions data from our top 200 suppliers. We have expanded this engagement to include additional key direct suppliers identified as a result of the Allergan, Inc and Actavis, plc integration. We have evaluated these data and have started to engage specific supply chain partners in benchmarking and data sharing. Our objective moving forward is to partner with our key suppliers on energy and greenhouse gas reduction initiatives.

WASTE MANAGEMENT AND RECYCLING

Hazardous Waste Trends
We achieved a 59% reduction in the intensity of hazardous waste generation (metric tonnes/sales) in 2015 compared to 2010. However, due to acquisitions, our absolute hazardous waste increased by 26%. This was primarily due to the addition of several operations as a part of the Actavis / Allergan integration in 2015. There was also significant increase in our production activities during this time. Comparing 2015 and 2014, our total hazardous waste generation consumption decreased by 10% year over year normalized to sales revenue.
**Nonhazardous Waste Trends**

We achieved a 60% reduction in the intensity of non-hazardous waste generation (metric tonnes/sales) in 2015 compared to 2010.

Our absolute nonhazardous waste generation during this same time frame reduced by 29%. This is a significant achievement considering the increases in production as well as the inclusion of several operations in 2015 as a part of the Allergan, Inc. Actavis, plc integration. Comparing 2015 and 2014, our total nonhazardous waste generation consumption decreased by 1% year over year normalized to sales revenue.

Several of our locations send zero waste to the landfill. Nonhazardous waste reduction is accomplished in two ways: 1) waste prevention through improved production yields and minimization of packaging, and 2) recycling. In 2015, Allergan recycled 4,717 metric tonnes of waste. This represents over 80% of non-hazardous waste generated.

### WATER MANAGEMENT

Water is an important resource for our operations. Our ophthalmic products are primarily composed of water. We have several operations in severe drought (water risk) locations. We have reduced water consumption through production efficiency improvements and reduced reliance on water-related utilities to control production conditions at operating locations. Through energy efficiency improvements, reheat and other heating requirements have been reduced, which has reduced the volumes of water required in steam, hot water and other ancillary systems used in production. Cooling tower cycles of efficiency have been increased through improved water treatment technology thus reducing the amount of cooling tower blow down. The same can be said of the boiler systems with improvement in efficiency reducing the amount of blow down as well as reducing the losses associated with the distribution system such as valves and steam traps. These efficiency improvements have allowed Allergan to continue to expand operations and grow at all locations. Reclaimed water has been used at the Irvine location for many years for irrigation purposes.

We achieved a 63% reduction in water withdrawal intensity (metric tonnes/sales) in 2015 compared to 2010. Our absolute water
withdrawal during this same time frame increased by 14% due to acquisitions. During this time we have had significant increases in our production as well as the inclusion of several operations in 2015 as a part of the Allergan, Inc, Actavis, plc integration. Comparing 2015 and 2014, our total water withdrawal decreased by 13% year over year normalized to sales revenue.

WATER CONSUMPTION

WASTE WATER DISCHARGE INDICATORS

We regularly monitor wastewater discharge from our operating locations to ensure compliance with regulatory requirements. We have implemented various best management practices including secondary containment, employee training, and operational controls to prevent wastewater contamination.

**Chemical Oxygen Demand Trend**

Chemical Oxygen Demand (COD), a measure of oxygen demanding chemicals in wastewater, has been reduced significantly due to wastewater equalization, neutralization and aeration facilities at applicable manufacturing facilities. The improvement in materials use efficiency has also helped to reduce the COD levels. Allergan is currently well below permitted discharge levels for COD at its facilities that monitor this parameter.

**Biochemical Oxygen Demand Trend**

Biochemical Oxygen Demand (BOD), a measure of oxygen demand through biochemical processes in wastewater, has been reduced significantly due to wastewater equalization and neutralization facilities at applicable manufacturing facilities. The improvement in materials use efficiency has also helped to reduce the BOD levels. Allergan is currently well below permitted discharge levels for BOD at its facilities that monitor this parameter.

**Total Suspended Solids Trend**

Total Suspended Solids (TSS) in wastewater discharges from Allergan facilities have been reduced significantly. The improvement in materials use efficiency has helped to reduce the TSS levels. Allergan is currently well below permitted discharge levels for TSS at all facilities that monitor this parameter.

AIR EMISSIONS INDICATORS

We regularly monitor relevant permitted air emissions from our operating locations to ensure compliance with regulatory requirements. Our emissions are well within allowable limits established by local operating permits and regulations.

**Volatile Organic Carbon Emissions**

Allergan is currently in compliance with all regulatory requirements regarding air emissions at its locations worldwide.

**Nitrogen Oxide (NOx) Emissions**

Allergan has negligible nitrogen oxide emissions from its facilities. These emissions are associated with fuel combustion regarding boiler operations primarily. The nitrogen oxide emissions are unregulated at most of the locations due to the low levels of these emissions.

**Sulfur Oxide (SOx) Emissions**

Allergan has negligible sulfur oxide emissions from its facilities. These emissions are associated with fuel combustion for its steam boiler operations primarily. The sulfur oxide emissions are unregulated at most of the locations due to the low levels of these emissions.
USE OF MERCURIAL PRESERVATIVES

We have significantly reduced the use of mercurial preservatives (Thimerosal, Phenylmercuric Acetate and Phenylmercuric Nitrate) in our products. Product reformulations, new product introductions without Thimerosal, Phenylmercuric Acetate and Phenylmercuric Nitrate and product attrition have accounted for this decline. We are continuing our reduction efforts and are targeting to eliminate mercurial preservatives in all our products by 2020.

ALLERGAN EHS PRODUCT DESIGN

In 2015 we started to integrate Allergan, Inc.’s Environmental, Health and Safety Product Design Criteria (EPDC) and the Actavis, plc process for reviewing EHS impact of products. The EPDC process evaluates products and formulations to identify opportunities for use of less hazardous ingredients, reduction of waste and water use, and reduction of packaging material. We will continue to refine this process in 2016.

KEEPING EMPLOYEES AND CONTRACTORS SAFE

Allergan continues our top quartile safety performance as measured by the number of injuries/illness requiring treatment beyond first aid. In 2015, we achieved an incident rate of 0.49 incidents per 100 employees. We also managed to reduce the number of more severe incidents as measured by the number of incidents requiring days away from work or restricted time to 0.26 incidents per 100 employees.

We have implemented several programs to proactively identify workplace hazards and reduce employee incidents.

These prevention programs include:

- Increasing awareness around Critical Safety Risks. Our Critical Safety Rules program focuses on 8 risks that can result in a serious incident or fatality. These areas include Process Safety, Confined Space Entry, Fall Protection, Electrical Safety, Hazardous Energy, Machine Guarding, and Powered Industrial Trucks.
- Implementation of Human and Organizational Performance (HOP) concepts and training.
- Encouraging employees to identify EHS risks through our Good Observations program. In 2015, over 65% of our employees submitted a Good Observation.
- Management conducting weekly Leadership Inspections (EHS Gemba Walks).
- Issuing EHS Alerts to share information on significant incidents.
- Forming learning teams to develop a deeper understanding of systemic failures associated with serious incidents and near miss events.
- Increasing employee awareness around workplace hazards and incidents. For example, one Allergan location identifies the location of incidents using signage. At another location, the incident investigation process includes a joint review of the incident area by the injured employee, area supervisor, area manager, environmental, health and safety and site senior management.
- Conducting detailed environmental, health and safety risk assessment of existing work-areas, as well as changes in processes or equipment.

KEEPING EMPLOYEES SAFE

<table>
<thead>
<tr>
<th>Year</th>
<th>Occupational Injury and Illness Incident Frequency Rate (cases per 200,000 hours worked)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>0.90</td>
</tr>
<tr>
<td>2011</td>
<td>0.98</td>
</tr>
<tr>
<td>2012</td>
<td>0.71</td>
</tr>
<tr>
<td>2013</td>
<td>0.57</td>
</tr>
<tr>
<td>2014</td>
<td>0.50</td>
</tr>
<tr>
<td>2015</td>
<td>0.49</td>
</tr>
</tbody>
</table>
17% HAND LACERATIONS
21% SLIPS/TRIPS/FALLS
4% EYE INJURIES
21% SUB MUSULO-SKELETAL
11% ACUTE MUSULO-SKELETAL
3% API EXPOSURE
6% STRUCK BY OBJECT/VEHICLE
2% FALL FROM HEIGHT
8% OTHER
7% CAR ACCIDENT

## CRITICAL SAFETY RULES

<table>
<thead>
<tr>
<th>Rule</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Process Safety</strong></td>
<td>When processing flammable solvents and/or combustible dusts do so only in appropriately rated areas with appropriately rated equipment. Use required controls to prevent ignition such as conductive containers and bonding and/or grounding straps to mitigate the potential for an ignition source. If a safety critical limit or alarm is reached do not proceed without consulting supervision or the procedure for an appropriate response.</td>
</tr>
<tr>
<td><strong>Confined Space Entry</strong></td>
<td>Confined Spaces must be identified, written confined space entry procedures established, trained on and followed prior to entry.</td>
</tr>
<tr>
<td><strong>Fall Protection</strong></td>
<td>Employees must use fall protection when exposed to a fall hazard of six feet (2 Meters) or more.</td>
</tr>
<tr>
<td><strong>Electrical Safety</strong></td>
<td>Only appropriately trained and authorized personnel are permitted to work on electrical equipment. Work on energized electrical equipment is prohibited without appropriate PPE and training.</td>
</tr>
<tr>
<td><strong>Hazardous Energy (Lock Out Tag Out)</strong></td>
<td>Bring all forms of hazardous energy (electrical, mechanical, pneumatic, hydraulic, thermal, chemical, pressure) to a Zero Energy State so it no longer presents a hazard and secure them with AUTHORIZED Locks and Tags before performing activities such as maintenance or cleaning activities.</td>
</tr>
<tr>
<td><strong>Machine Guarding &amp; Interlocks</strong></td>
<td>Employees shall not tamper with, remove, bypass or disable machine guarding or safety interlocks while operating equipment under normal conditions.</td>
</tr>
<tr>
<td><strong>Powered Industrial Trucks (PITs) and Suspended Loads</strong></td>
<td>Employees are only allowed to operate PITs for which they are certified. Do not work on or under suspended loads. Ensure measures are in place to prevent trailers from moving during trailer loading/unloading.</td>
</tr>
<tr>
<td><strong>Hazardous Atmospheres</strong></td>
<td>Identify all areas/operations with the potential for a hazardous atmosphere (potential for a SIF). Ensure mechanisms are in place to warn employees if/when the hazardous atmosphere exists. Do not enter/immediately evacuate an area where the atmosphere is dangerous to life and health (i.e., Asphyxiant gases–Nitrogen, Toxic gases–Carbon, Cyanide etc.).</td>
</tr>
</tbody>
</table>
DIVERSITY, TRAINING, DEVELOPMENT AND RECOGNITION

The strength of our organization rests upon our more than 16,000 diverse, talented and committed employees. We are committed to a diverse and inclusive workplace – where colleagues of all backgrounds have the opportunity to be successful. In 2015, women comprised 52% of our workforce and 49% of our leadership roles. This includes more than 50% of our manager and director roles, and nearly 25% of our executive positions. We were also fortunate to have two exceptional female members on our Board of Directors who bring truly exceptional credentials to our organization and are committed to its development. Also, 35% of our employees worldwide have worked at Allergan for more than 7 years.

Learning & Development

Allergan is committed to being an inclusive and developmentally rewarding place to work. Our lean and efficient structure encourages responsibility and accountability that enables each and everyone to make an individual and collective difference with the opportunity to be noticed and recognized for accomplishments. A comprehensive learning management system has been implemented to ensure consistent and comprehensive compliance and technical training takes place, and provides powerful reporting tools. In 2015, our employees averaged over 25 hours of training to further their development. We also offered 50 training classes focused on management and leadership. We have made additional investments in career and leadership development and have rolled out a model and curriculum to ensure all of our employees have significant opportunities to grow and develop, and that Allergan has the talent pool necessary to sustain its growth. We are also committed to providing competitive rewards for our employees. Our compensation programs are market-driven, reward our employees for superior performance and align with shareholder value creation.
BIOETHICS

Allergan is committed to strong bioethical practices. When working with biological agents, organisms, and toxins, it is done in the safest manner possible. Allergan is committed to minimizing the risks associated with work involving biological agents, organisms, and toxins and these risks are managed to the highest practical level. Allergan adheres to strict compliance with international and national regulations and guidelines regarding design and operation of these types of facilities. The Company also ensures consistency between Allergan groups and sites using biological agents, organisms, and toxins. The same standards apply at all Allergan facilities. Allergan continues to evaluate existing practices against current and state of the art practices.

Allergan meets Center for Disease Control (CDC) requirements and is licensed by the CDC to manage biological organisms and toxins. Allergan follows the Biosafety in Microbiological and Biomedical Laboratories (BMBL) requirements for all aspects of the work conducted in these areas.

CORPORATE STATEMENT ON ANIMAL TESTING

The U.S. Food and Drug Administration (FDA) and other worldwide health regulatory agencies currently require all pharmaceutical manufacturers to protect patients and consumers by establishing product quality, safety and effectiveness through approved and validated testing methods, which may include animal testing.

When animal work is necessary it is designed to ensure the highest standards of animal welfare and undergoes ethical review, approval and oversight from an Institutional Animal Care and Use Committee (IACUC).

Allergan shares the pharmaceutical industry’s goal of reducing or eliminating animal testing wherever possible and is committed to the “3Rs” principles of refinement, reduction and eventual replacement of laboratory animals in product testing. In this regard, Allergan has developed and gained regulatory approvals of a cell-based potency assay to replace an animal-based assay for use in the ongoing manufacturing of BOTOX®.
PHILANTHROPY AND CITIZENSHIP

The Allergan Foundation (TAF) has made grants focusing support in four philanthropic areas: the arts, civic programs, education, and health and human services. As part of The Allergan Foundation’s commitment to health and human services, the Foundation also supports selected initiatives, known as “Focus Grants,” to improve patient diagnosis, treatment, care, and quality of life, or to otherwise promote access to quality health care.

**Priority 1** is to support local health and human services efforts through donations and grants as well as through collaborations with businesses and health organizations to promote well-being and help meet unmet medical needs. These efforts are focused worldwide and not strictly based on Allergan internal operational areas.

**Priority 2** is to support local educational programs and services through donations and grants as well as through collaborations and volunteer-advocacy by employees both company supported and time given by employees. These efforts are engaged in all local and regional areas where Allergan conducts research, manufactures and conducts commercial business.

**Priority 3** is to support local arts and arts and civic programs and services through donations and grants as well as through collaborations and volunteer-advocacy by employees both company supported and time given by employees. These efforts are engaged in all local and regional areas where Allergan conducts research, manufactures and conducts commercial business.

At Allergan, the focus on cutting-edge science, sound business practices and a global perspective contribute to the Company’s ultimate goal – to make a positive impact on the health and well-being of people around the world. At The Allergan Foundation, we mirror this perspective through the funding of programs and services benefiting communities and improving lives in the areas where Allergan’s employees live and work. In 2015, as a result of the ongoing commitment of Allergan and its employees around the world, we supported 285 organizations with more than $7.5 million in funding, extending the reach of The Allergan Foundation’s philanthropic commitment even further.
The Allergan Foundation receives hundreds of Community Grant applications each year, and thoughtful consideration is given to each request. Grants are awarded in four areas of funding: education, the arts, civic and community, and health and human services, with special attention given to the work of organizations that connect resources with underserved, vulnerable populations. A sample of the programs and organizations that were funded are as follows: Art4Kids provides art materials that are used in conjunction with therapy for children in shelters, hospitals, and treatment facilities; the Alzheimer's Family Services Center provides affordable access to high-quality, culturally-appropriate dementia healthcare and supportive services that help families maintain their health, financial security, and quality of life; through our funding of the Heart of Texas Community Health Center, vulnerable pregnant women can obtain needed dental care; the Children’s Burn Foundation provides medical, surgical and psycho-social treatment for child burn survivors locally, nationally and internationally.

The Allergan International Foundation (AIF) continued the global extension of The Allergan Foundation’s philanthropic efforts to providing a lasting and positive impact on communities around the world. AIF distributed approximately $500,000 in support of a broad range of initiatives that bring aid and relief to underserved communities and share The Allergan Foundation’s considerable philanthropic concern with the global community.

The AIF is active in the same four philanthropic areas: the arts, civic programs, education and health and human services, in which it promotes access and improvements to quality health care, diagnosis and treatment, education, research, quality of life and disease awareness.

For both TAF and AIF, grants are awarded to charitable organizations with high-quality programs and services, well-defined goals, a commitment to maximising available resources, and a reputation for meeting objectives and reporting measured results. The objectives and programs of any requesting organization must be clearly defined and the program objectives must be achievable.

Organizations that AIF is proud to be supporting include: The Westport Family & Community Resource Centre, Bobath Children’s Therapy Centre Wales, Retina South Africa, Operation Smile (Ethiopia), Eye Bank Foundation of the Philippines, Americare India Foundation, and Patrulla Aera Civil Colobiana, among others. AIF continually looks to expand its philanthropic efforts into each country where Allergan plc has an office and employees to support worthy causes in those areas.

Leadership of The Allergan Foundation is headed up by Brent Saunders, President and Chief Executive Officer, Allergan plc, who is Chairman of the Board of TAF. Joining him on the Board are: Bob Bailey, EVP, Chief Legal Officer, Allergan plc; Tessa Hilado, EVP, Chief Financial Officer, Allergan plc; Alex Kelly, EVP, Chief Communications Officer, Allergan plc; Karen Ling, EVP, Chief Human Relations Officer, Allergan plc; and Sanjiv Patel, EVP, Chief Strategy Officer, Allergan plc. Additionally, serving on the Allergan Foundation Board of Directors since 2011, is Mr. Gavin S. Herbert, Founder of Allergan, Inc. A pioneer and visionary in the field of health care, Mr. Herbert brings with him an unparalleled wealth of knowledge and insight, and provides strong support for our work in philanthropic decision-making. The Allergan Foundation is grateful for his active involvement and appreciates Mr. Herbert’s continued service to the broader community.
The Allergan Foundation will consider awarding grants for programs that:

- Promote education, research, and awareness of eye care, CNS, GI and Cystic Fibrosis, dermatology, aesthetics, women’s health, urology, cardiovascular, infectious disease, as well as selected other therapeutic areas.
- Improve the quality of health care and patient access to care.
- Enhance and strengthen the communities where Allergan plc. has a facility or employees by contributing to the arts, education, and other civic and community causes.

Grant Limitations

Grants are not made to support or fund:

- Organizations that are not 501(c)(3) publicly supported charities
- Individual or family requests for scholarships, fellowship assistance, or other types of support
- Refugee- or religious-based activities for the purpose of furthering religious doctrine
- Fraternal, labor, or political organizations
- Organizations that discriminate on the basis of race, religion, creed, gender, or national origin
- Matching gifts
- University administrative, management, or indirect fees
- Golf tournaments, athletic events, league or team sponsorships, or school-affiliated orchestra, band, choir, student trips, or tours

Grants generally are not approved for:

- Private schools K–12
- Fundraising acts or advertising sponsorships
- Activities that propagandize, influence legislation and/or elections; promote voter registration; political candidates, political campaigns or engaged in political activities; litigation
- Institutions limiting their services to persons of a single religious sect or denomination
- Promotional exhibits, surveys, or consumer interest groups
- Endowments, capital, or building campaigns
- Contingencies, deficits, or debt reduction
- Charities or funds solely directed by a single physician or medical practice group
- Agencies, projects or programs primarily financed by government sources

Additional Information

The objectives and programs of the requesting organization must be clearly defined and reasonably capable of achievement. The financial status of the requesting organization and its sources of income must also meet applicable legal requirements, including proof of tax-exempt status under section 501(c)(3), as a public charity described in sections 509(a)(1) or 509(a)(2) of the Internal Revenue Code, and status as a nonprofit organization under applicable state law. In assessing potential grant recipients, The Allergan Foundation considers the extent of the public benefit provided by the requesting organization. An effective governing board, efficient management, and strong community support are also among the criteria considered.

TAF evaluates the impact to the community and the intended recipients of the donation or grant and its intended purpose. Grants are competitively compared even if the minimum grant requirements are met in order to determine which requests are
going to have the greatest impact. Outcomes are measured periodically and randomly against the request proposals in order to determine if the intended purpose is achieved and how successfully.

Allergan’s reputation is measured qualitatively through periodic and random surveys with local community efforts in order to gauge the effectiveness of participation and improving the selection process. The Allergan Foundation reserves the right, in its sole discretion, to reject any request even when the requesting organization meets The Allergan Foundation’s grant guidelines.

“WE CARE” Grants
The Allergan Foundation also evaluates requests for funding to organizations in which employees of Allergan, Inc. take a strong interest through their personal donations of time. With its “WE CARE” program, The Allergan Foundation considers financial grants to such organizations annually, based on applications submitted by a US-based employee of Allergan, plc. “WE CARE” grants are usually made in amounts ranging from $500 to $1,500.

Product Donations
In 2015, Allergan provided product donations to non-profit and relief organizations worldwide, totaling 282,157 Allergan product units such as Acular, Alphagan, Lumigan, Combigan, Refresh, Restasis, and other product lines. The number of organizations supported in these efforts totals more than 222 non-profit and relief organizations. Allergan has a breakdown of the organizations and the type and quantity of Allergan products that were received. Allergan does not wish to share this detailed information.

Looking to the future, The Allergan Foundation stands secure with more than $40 million in assets, allowing us to continue supporting a broad base of important work. Focused intently on a spirit to improve lives and elevate communities and on behalf of the Board of Directors, we are grateful for this opportunity, and we are proud to stand with the organizations and individuals making a difference in the world.
ACCESS TO MEDICINES – OUR SOCIAL CONTRACT

Our biopharma industry is vital and has made profound contributions that have increased life expectancy and dramatically improved health.

Allergan is committed to innovation, access, and responsible pricing ideals. This commitment is translated into the four principles of Our Social Contract, which begins when there is a patient with an unmet need.

These are our commitments to the medical professionals and patients who count on us to continue finding new treatments for their most pressing medical needs.

THE FOUR PRINCIPLES:
1. Invest & Innovate
2. Access & Pricing
3. Quality & Safety
4. Education

1. Invest & Innovate
Our social contract begins where there is a patient with an unmet need. As we identify needs in our areas of expertise, we are committed to risking billions of dollars to develop life-enhancing innovations. We will do so in the U.S. and around the world. And, we use our Open Science model to access promising inventions that exist outside of Allergan. That means rewarding the scientists, start-up companies, academic institutions, investors and partners for the work they have put into the original invention, which becomes part of the cost of developing life enhancing innovations.

That investment doesn’t stop when a drug is first approved by a regulator. For many treatments, we invest more money in R&D after regulatory approval than we do before the first regulatory approval. For example, while our product Vraylar was recently approved to treat bipolar mania and schizophrenia, we continue to make major investments to study Vraylar for other mental health conditions where it may help people – these include major depressive disorder, bipolar depression and negative symptoms of schizophrenia. There is no guarantee that any of those studies will yield new approved treatment options for patients. That is the risk we take when we invest hundreds of millions of dollars to develop medicines. But for us, it is still a risk worth taking. As important, it is our responsibility as part of the social contract with people who are hoping for a better, healthier life.

2. Access & Pricing
We commit to making these branded therapeutic treatments accessible and affordable to patients while also ensuring that we can continue to meet our ‘invest and innovate’ obligations outlined in Principle 1. We commit to these responsible pricing ideals for our branded therapeutics.

• We will price our products in a way that is commensurate with, or lower than, the value they create by mitigating or avoiding the need for other treatment modalities or providing better quality of life to those patients without other treatment options.
• We will enhance access to patients. This means that Allergan will enhance our patient assistance programs in 2017 to match the current industry leader(s).
• We will work with policy makers and payers to facilitate better access to our medicines.
• We will not engage in price gouging actions or predatory pricing.
• We commit to providing an aggregate view of the net impact of price on our business at least annually.
• We will limit price increases. Where we increase price on our branded therapeutic medicines, we will take price increases no more than once per year and, when we do, they will be limited to single-digit percentage increases. Our expectation is that the overall cost of our drugs, net of rebates and discounts, will not increase by more than low-to-mid single digits percentages per year, slightly above the current annual rate of inflation.
• We will not engage in the practice of taking major price increases without corresponding cost increases as our products near patent expiration. While we have participated in this industry practice in the past, we will stop this practice going forward. Where new regulatory requirements impose added costs, we will seek to reflect those costs in our pricing.
3. Quality & Safety
We commit to intensely monitoring the safety of our medicines, before they are approved by regulators and afterward. We commit to promptly reporting and acting on new safety data so that patients can trust our medicines. We also commit to maintaining high standards of quality for each of our products. And, we commit to maintaining a continuous supply of our medicines by investing to expand manufacturing capacity of our products, either directly or through our manufacturing partners.

4. Education
We are committed to appropriately educating physicians about our medicines so that they can be used in the right patients for the right conditions.

ADDRESSING PATIENT NEEDS

Patient Resources Source – Allergan website
At Allergan, we believe the best of medicine is realized when patients have the information they need to make well-informed decisions regarding their treatment options. Information can be found throughout our Website about our products and the conditions they treat, along with helpful links to additional patient education and support resources.

Since Allergan’s inception, bringing the best of medicine to the forefront of patient care has always entailed a commitment to interaction and involvement: Listening to doctors and addressing patients’ needs. We work diligently to make sure we are providing the tools and channels to keep the conversation as dynamic and direct as possible.

For patients who cannot afford our medicines Allergan offers a patient assistance program (PAP) and copay assistance for many of our medicines for eligible patients. Patients can visit AllerganAccess.com for many of our patient savings cards (copay cards), or apply to Allergan’s PAP.

Physician Resources Source – Allergan website
Underlying our commitment is a drive to help medical specialists improve patient outcomes. We pursue this goal through ongoing training about our products, hands-on workshops by experts to stimulate scientific exchange and sharing of best practices, and support for medical education and ongoing studies. The ALLERGAN ACADEMY™ education programs, for example, offer a forum for peer-to-peer discussion and a comprehensive curriculum in-person and via the Web for plastic surgeons to learn more about our breast aesthetic portfolio. The ALLERGAN ACADEMY™ education programs also facilitate the Allergan Physician Certification Program, which grants surgeons access to the NATRELLE™ Collection of saline and silicone gel-filled breast implants upon completion.
Allergan conducts research to understand the impact of our products on patient care in our disease areas of focus. The Global Health Economics and Outcomes Research (GHEOR) organization leads the effort to define the value of our products through the understanding of humanistic and economic outcomes. Specifically, humanistic outcomes seek to understand the impact of a product or disease on a person’s life whereas economic outcomes seek to understand the economic implications of a treatment or disease on the healthcare system. This process is extensive and covers all Allergan products as early as development and throughout the products life-cycle. The defined strategies are evaluated several times a year to ensure that the necessary data is generated and if additional research needs to be undertaken to support the clinical, humanistic and economic benefits of Allergan products.

One key area of focus includes the development and assessment of patient reported outcomes (PRO), in order to understand the impact of the disease or a drug on patient’s lives. In addition, their GHEOR team conducts economic analyses and develops models to understand cost implications of Allergan products. The use of real world evidence (RWE) informs Allergan’s understanding of the effectiveness of approved products as well as cost-offsets of a drug which may not appear in clinical trials.

Allergan uses this research in our interactions with regulatory agencies such as the FDA and Ministries of Health worldwide as well as payors and reimbursement decision makers worldwide. Internationally, this research is valuable for Health Technology Assessments conducted by agencies such as NICE, SMC, PBAC to ensure they receive accurate information on the value of Allergan products. In the US, this research is incorporated into AMCP Dossiers available to payors in the form of an unsolicited request for use in formulary decision making.

The majority of evidence generation at Allergan occurs in the following areas: Clinical Development and the Chief Medical Office (includes Global Health Economics and Outcomes Research, Medical Affairs and Global Patient Safety & Epidemiology). Allergan’s investment in this area ensures that there is an understanding of the value of our products and their appropriate use.
GHEOR works with cross-functional colleagues across Allergan’s key therapeutic areas to generate the evidence needed to communicate the value of Allergan products. This involves projects related to Dermatology and Aesthetics; Central Nervous System; Eye Care; Women’s Health and Urology; Gastroenterology and Cystic Fibrosis; and Cardiovascular disease and Infectious disease. Clinical Trials and post treatment follow on studies are included at the following website: http://www.clinicaltrials.gov/. These are being continually updated with the latest information.

BIODIVERSITY

Allergan has facilities and offices located in major cities and in rural locations. Allergan has established a position to preserve biodiversity on an ongoing basis at our operations. Allergan assures that risks associated with land use, operations and impacts to biodiversity are identified and mitigated. Allergan assures compliance with international, national and local regulations and guidelines regarding biodiversity protection and preservation. Allergan assures open space and green areas are included in land use planning at our operations. Allergan assures consistency between Allergan sites regarding land use. Allergan also continues to evaluate our existing practices against current state of the art practices. Allergan has had extensive involvement in onsite activities to preserve green space and encourage community preservation of open green space such as the Lake Waco Wetlands Habitat Preservation project supported by Allergan Pharmaceuticals Waco Texas volunteers with support from Allergan. As well as the Newport Back Bay Conservancy located in Irvine California and the Allergan Pharmaceuticals Ltd Westport Ireland volunteers that support rainforest preservation and local biodiversity preservation. Allergan agrees with the principles included in the UN Convention on Biodiversity and strives to meet these principles.

RECOGNIZING EXCELLENCE

Allergan’s corporate culture is steeped in a rich tradition of excellence, hard work, and a dedication to improving quality of life. As a result, we seek to encourage innovation, personal and career growth, and a sense of meaning that goes far beyond our walls. Allergan was built on the commitment of meeting unmet medical needs. Today, we continue this tradition by recognizing those employees who believe that an idea can change the world.

The work of our outstanding scientists and inventors is also recognized by their peers at our annual Authors’ and Inventors’ Reception. Across our sales organization, there are also several programs in place to recognize and reward those who are positively contributing to the business.

CONCLUSION

As we conclude our 2011–2015 Sustainability Strategic Cycle and transition to our 2020 Sustainability Program, we celebrate our successes and focus on further improving our performance. 2015 was a year full of significant organizational changes and integration. Despite these challenges, we continued to improve our performance. We’re looking forward to 2016 as another opportunity to further integrate our sustainability program across the organization and establish a strong platform for achieving our vision for 2020.
## SUSTAINABILITY PERFORMANCE SUMMARY TABLE

<table>
<thead>
<tr>
<th>SUSTAINABILITY PERFORMANCE INDICATOR</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Safety Management</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Occupational Injury and Illness Incident</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frequency Rate</td>
<td>0.90</td>
<td>0.98</td>
<td>0.71</td>
<td>0.57</td>
<td>0.77</td>
<td>0.49</td>
</tr>
<tr>
<td>DART Case Rate</td>
<td>0.39</td>
<td>0.75</td>
<td>0.46</td>
<td>0.24</td>
<td>0.22</td>
<td>0.26</td>
</tr>
<tr>
<td><strong>Waste Management</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hazardous Waste (tonnes)</td>
<td>532</td>
<td>336</td>
<td>361</td>
<td>317</td>
<td>687</td>
<td>670</td>
</tr>
<tr>
<td>HW per Sales (tonnes/million sales)</td>
<td>0.11</td>
<td>0.06</td>
<td>0.06</td>
<td>0.05</td>
<td>0.05</td>
<td>0.04</td>
</tr>
<tr>
<td>Solid Waste (tonnes)</td>
<td>1,421</td>
<td>1,241</td>
<td>1,155</td>
<td>1,271</td>
<td>945</td>
<td>1,014</td>
</tr>
<tr>
<td>SW per Sales (tonnes/million sales)</td>
<td>0.29</td>
<td>0.23</td>
<td>0.20</td>
<td>0.21</td>
<td>0.07</td>
<td>0.07</td>
</tr>
<tr>
<td>Recycling (tonnes)</td>
<td>3,600</td>
<td>4,196</td>
<td>3,806</td>
<td>3,980</td>
<td>4,847</td>
<td>4,717</td>
</tr>
<tr>
<td>Recycling Rate (%)</td>
<td>71.70</td>
<td>77.17</td>
<td>76.72</td>
<td>76.07</td>
<td>83.00</td>
<td>83.00</td>
</tr>
<tr>
<td><strong>Energy Management</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electrical Energy (GJ)</td>
<td>488,503</td>
<td>92,702</td>
<td>507,655</td>
<td>525,558</td>
<td>667,262</td>
<td>675,378</td>
</tr>
<tr>
<td>Electrical Energy per Sales (GJ/million sales)</td>
<td>99</td>
<td>91</td>
<td>89</td>
<td>85</td>
<td>48</td>
<td>45</td>
</tr>
<tr>
<td>Fuel Consumption (GJ)</td>
<td>455,525</td>
<td>476,943</td>
<td>480,323</td>
<td>494,248</td>
<td>631,570</td>
<td>635,877</td>
</tr>
<tr>
<td>Fuel per Sales (GJ/million sales)</td>
<td>92.61</td>
<td>88.01</td>
<td>84.14</td>
<td>79.75</td>
<td>45.57</td>
<td>42.20</td>
</tr>
<tr>
<td>Total Energy Consumption (GJ)</td>
<td>944,028</td>
<td>969,645</td>
<td>987,978</td>
<td>1,019,807</td>
<td>1,298,832</td>
<td>1,311,256</td>
</tr>
<tr>
<td><strong>Water Management</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water (M3)</td>
<td>884,818</td>
<td>961,027</td>
<td>988,319</td>
<td>986,080</td>
<td>1,073,671</td>
<td>1,012,012</td>
</tr>
<tr>
<td>Water per Sales (M3 million sales)</td>
<td>180</td>
<td>177</td>
<td>173</td>
<td>159</td>
<td>77</td>
<td>67</td>
</tr>
<tr>
<td><strong>Compliance Management</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Notices of Violation</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>EHS Compliance Penalties/Fines ($)</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
</tr>
<tr>
<td>Remediation Settlements ($)</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
</tr>
<tr>
<td><strong>Carbon Management</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scope 1 Greenhouse Gas Emissions (MTCO2E) – Direct from Fuel Combustion (R&amp;D/Manufacturing)</td>
<td>23,423</td>
<td>24,536</td>
<td>24,659</td>
<td>25,244</td>
<td>33,808</td>
<td>32,443</td>
</tr>
<tr>
<td>Scope 2 Greenhouse Gas Emissions (MTCO2E) - Indirect from Electrical Consumption (R&amp;D/Manufacturing)</td>
<td>50,234</td>
<td>48,173</td>
<td>48,212</td>
<td>49,367</td>
<td>63,178</td>
<td>68,444</td>
</tr>
<tr>
<td>Total Greenhouse Gas Emissions (MTCO2E) – Total (R&amp;D/Manufacturing)</td>
<td>73,657</td>
<td>72,709</td>
<td>72,871</td>
<td>74,611</td>
<td>96,986</td>
<td>100,887</td>
</tr>
<tr>
<td>Total Greenhouse Gas Emissions per Sales (MTCO2E/$million) (R&amp;D / Manufacturing)</td>
<td>15</td>
<td>13</td>
<td>13</td>
<td>12</td>
<td>7</td>
<td>6.7</td>
</tr>
<tr>
<td>Scope 1 Greenhouse Gas Emissions (MTCO2E) – emission from all activities (verified by ERM CVS)</td>
<td>45,309</td>
<td>49,128</td>
<td>49,828</td>
<td>49,828</td>
<td>87,835</td>
<td>86,023</td>
</tr>
<tr>
<td>Scope 2 Greenhouse Gas Emissions (MTCO2E) – emission from all activities (verified by ERM CVS)</td>
<td>51,744</td>
<td>52,049</td>
<td>55,049</td>
<td>68,979</td>
<td>86,591</td>
<td></td>
</tr>
<tr>
<td>Scope 3 Greenhouse Gas Emissions - Supply Chain (tonnes)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>145,878</td>
<td>250,000</td>
<td>250,000</td>
</tr>
<tr>
<td>Green Power Consumption (% of Total Power Consumed)</td>
<td>13</td>
<td>13</td>
<td>17</td>
<td>20</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td><strong>Risk Assessment/Corrective Action Management</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of EHS Risk Assessments</td>
<td>47</td>
<td>109</td>
<td>264</td>
<td>153</td>
<td>161</td>
<td>246</td>
</tr>
<tr>
<td>Number of EHS related Corrective/Preventive Actions</td>
<td>-</td>
<td>133</td>
<td>542</td>
<td>693</td>
<td>653</td>
<td>1,600</td>
</tr>
<tr>
<td><strong>Diversity</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Board Diversity - Women %</td>
<td>17</td>
<td>17</td>
<td>20</td>
<td>11</td>
<td>11</td>
<td>17</td>
</tr>
<tr>
<td>Gender Diversity (% Female)</td>
<td>-</td>
<td>52</td>
<td>52</td>
<td>53</td>
<td>53</td>
<td>52</td>
</tr>
<tr>
<td>Leadership Roles Gender Diversity (% Female)</td>
<td>-</td>
<td>39</td>
<td>39</td>
<td>40</td>
<td>51</td>
<td>49</td>
</tr>
<tr>
<td>Tenure at Allergan (% &gt; 7 Years)</td>
<td>-</td>
<td>30</td>
<td>33</td>
<td>30</td>
<td>34</td>
<td>35</td>
</tr>
<tr>
<td><strong>Sales ($000s)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sales ($000s)</td>
<td>$4,919,000</td>
<td>$5,419,100</td>
<td>$5,708,800</td>
<td>$6,197,500</td>
<td>$13,858,000</td>
<td>$15,067,000</td>
</tr>
<tr>
<td>Head Count</td>
<td>9,225</td>
<td>10,088</td>
<td>11,401</td>
<td>11,600</td>
<td>-15,000</td>
<td>16,325</td>
</tr>
</tbody>
</table>

1. Data only for Manufacturing, R&D operations unless otherwise noted
2. 2010–2013 data only for legacy Allergan, Inc operations.
3. 2014 data has been adjusted to include data from Actavis operations that have remained as a part of Allergan
Verification Scope
ERM Certification & Verification Services (ERM CVS) was commissioned by Allergan, Inc. (Allergan) to verify its 2015 consolidated global GHG inventory data as reported in Section CC8.2 and CC8.3 of its CDP response. The reporting period was January 1, 2015–December 31, 2015 and covered emissions of CO2, N2O, CH4, SF6, PFCs, and HFCs from direct, Scope 1 sources (fossil fuel combustion, refrigerants, processes, company-owned vehicles) and indirect, Scope 2 sources (purchased electricity and steam) for Allergan’s operations.

The assessment covered the following GHG accounting elements:
• Reporting Boundary;
• GHG Management System and Data Collection Processes;
• Data and GHG Emissions Quantification;
• Reporting Criteria; and
• Quality Assurance and Data Uncertainty

This assurance engagement involved
• a review of consolidated group data at Allergan’s office and R&D/ manufacturing facility in Irvine, California, as well as interviewing corporate staff.
• detailed review of data from manufacturing facilities, including site visits to review data at Allergan’s R&D/manufacturing facilities at Irvine, California, and Westport, Ireland.

Our work involved detailed review and substantiation of information through selected interrogation of both source and consolidated data in conjunction with interviews with relevant staff. Data representing more than 86% of Scope 1 emissions and 74% of Scope 2 emissions were subject to selected substantiation of supporting evidence.

Verification Objectives
• To determine the conformity of the GHG inventory with the reporting criteria.
• To assess completeness of the GHG inventory.
• To evaluate the GHG information system and its controls/management.
• To confirm whether the GHG assertion is without material discrepancy and whether the verification activities provide the level of assurance agreed to.

Greenhouse Gas Reporting Criteria
GHG data has been reported based on the WRI/WBcSD GHG Protocol and the International Organization for Standardization (ISO) 14064-1, Specification with guidance at the organization level for quantification and reporting of greenhouse gas emissions and removals.

Greenhouse Gas Verification Criteria
Verification activities were based on ISO 14064-3: Specification with guidance for the validation and verification of greenhouse gas assertions.

Level of Assurance
Our Independence
ERM CVS is a member of the ERM Group. This is the third year that ERM CVS has been engaged by Allergan to provide an opinion statement with respect to its Scope 1 and Scope 2 GHG emissions data. The work that ERM CVS conducts for clients is solely related to independent assurance activities and training programmes related to auditing techniques and approaches. Our processes are designed to ensure that the work we undertake with clients is free from bias and conflict of interest. ERM CVS and the staff that have undertaken work on this assurance exercise provide no consultancy related services to Allergan in any respect.

A reasonable level of assurance was applied during verification performance.

Organizational Boundaries
Allergan has consolidated its global GHG inventory according to the operational control approach, excluding the facilities in its generic medicines portfolio. A list of facilities included in Allergan’s GHG inventory can be found in Appendix A.

Assurance Conclusion
Based on the approach described above, and the GHG reporting criteria applied, it is ERM CVS’s opinion that the reported Scope 1 and Scope 2 GHG data set out in Section CC8.2 & CC8.3 of Allergan’s CDP response for its global operationally controlled facilities (excluding those facilities in its generic medicines portfolio) are free from material misstatement.

Scope 1 Emissions: 86,023 tonnes CO2-e
Scope 2 Emissions (location-based): 90,546 tonnes CO2-e
Scope 2 Emissions (market-based): 86,591 tonnes CO2-e

Data and information supporting the GHG assertion were calculated based on measured as well as estimated data.

Observations
Without compromising our conclusion above, we make the following observations:
• The overall data consolidation process would benefit from updating the GHG inventory management plan to include stronger QA/QC procedures and more explicit methodology descriptions to ensure consistent calculation methods and factors from all sources.
• Allergan is exploring automating the process of incorporating invoice data into its GHG data management system (ALLEHS). Implementing this change and continuing to explore ways to automate data handling will minimize data handling errors.

Based on our work outlined above, we have provided Allergan with a separate, confidential GHG Verification Report detailing our assessment of Allergan’s GHG emissions data (calendar year 2015).

Limitations of Assurance Statement
The findings presented here are not intended to be used as advice or as the basis for any decisions, including, without limitation, financial or investment decisions.

2016 SUSTAINABILITY REPORT
## APPENDIX A: ALLERGAN FACILITIES INCLUDED IN THE GHG INVENTORY

<table>
<thead>
<tr>
<th>NO.</th>
<th>FACILITY NAME / EMISSION SOURCE</th>
<th>FACILITY TYPE</th>
<th>LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Irvine</td>
<td>Manufacturing/R&amp;D</td>
<td>Irvine, CA</td>
</tr>
<tr>
<td>2</td>
<td>Waco</td>
<td>Manufacturing/R&amp;D</td>
<td>Waco, TX</td>
</tr>
<tr>
<td>3</td>
<td>San Jose, CA</td>
<td>Manufacturing/R&amp;D</td>
<td>San Jose, CA</td>
</tr>
<tr>
<td>4</td>
<td>Brazil</td>
<td>Manufacturing/R&amp;D</td>
<td>Guarulhos, SP Brazil</td>
</tr>
<tr>
<td>5</td>
<td>Costa Rica</td>
<td>Manufacturing/R&amp;D</td>
<td>La Aurora de Heredia, Costa Rica</td>
</tr>
<tr>
<td>6</td>
<td>Pringy</td>
<td>Manufacturing/R&amp;D</td>
<td>Pringy, France</td>
</tr>
<tr>
<td>7</td>
<td>Westport</td>
<td>Manufacturing/R&amp;D</td>
<td>Westport, Ireland</td>
</tr>
<tr>
<td>8</td>
<td>Fall River</td>
<td>Manufacturing/R&amp;D</td>
<td>Fall River, MA</td>
</tr>
<tr>
<td>9</td>
<td>Cincinnati</td>
<td>Manufacturing/R&amp;D</td>
<td>Cincinnati, OH</td>
</tr>
<tr>
<td>10</td>
<td>Costa Mesa</td>
<td>Manufacturing/R&amp;D</td>
<td>Dallas, TX</td>
</tr>
<tr>
<td>11</td>
<td>Liege</td>
<td>Manufacturing/R&amp;D</td>
<td>Liege, Belgium</td>
</tr>
<tr>
<td>12</td>
<td>Houston</td>
<td>Manufacturing/R&amp;D</td>
<td>Houston, TX</td>
</tr>
<tr>
<td>13</td>
<td>Liverpool</td>
<td>Manufacturing/R&amp;D</td>
<td>Liverpool, UK</td>
</tr>
<tr>
<td>14</td>
<td>Weiterstadt</td>
<td>Manufacturing/R&amp;D</td>
<td>Weiterstadt, Germany</td>
</tr>
<tr>
<td>15</td>
<td>Costa Mesa</td>
<td>Office</td>
<td>Costa Mesa, CA</td>
</tr>
<tr>
<td>16</td>
<td>Carlsbad</td>
<td>Office</td>
<td>Carlsbad, CA</td>
</tr>
<tr>
<td>17</td>
<td>Westlake Village</td>
<td>Office</td>
<td>Westlake Village, CA</td>
</tr>
<tr>
<td>18</td>
<td>Aliso Viejo</td>
<td>Office</td>
<td>Aliso Viejo, CA</td>
</tr>
<tr>
<td>19</td>
<td>San Francisco</td>
<td>Office</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>20</td>
<td>Mt Laurel</td>
<td>Office</td>
<td>Mt Laurel, NJ</td>
</tr>
<tr>
<td>21</td>
<td>Rockaway</td>
<td>Office</td>
<td>Rockaway, NJ</td>
</tr>
<tr>
<td>22</td>
<td>North Brunswick</td>
<td>Office</td>
<td>North Brunswick, NJ</td>
</tr>
<tr>
<td>23</td>
<td>Jersey City</td>
<td>Office</td>
<td>Jersey City, NJ</td>
</tr>
<tr>
<td>24</td>
<td>Bridgewater</td>
<td>Office</td>
<td>Bridgewater, NJ</td>
</tr>
<tr>
<td>25</td>
<td>Grand Island</td>
<td>Office</td>
<td>Grand Island, NY</td>
</tr>
<tr>
<td>26</td>
<td>Farmingdale</td>
<td>Office</td>
<td>Farmingdale, NY</td>
</tr>
<tr>
<td>27</td>
<td>Hauppauge</td>
<td>Office</td>
<td>Hauppauge, NY</td>
</tr>
<tr>
<td>28</td>
<td>Austin</td>
<td>Office</td>
<td>Austin, TX</td>
</tr>
<tr>
<td>29</td>
<td>Canada</td>
<td>Office</td>
<td>Ontario, Canada</td>
</tr>
<tr>
<td>30</td>
<td>Mexico</td>
<td>Office</td>
<td>Mexico City, Mexico</td>
</tr>
<tr>
<td>31</td>
<td>Argentina</td>
<td>Office</td>
<td>Buenos Aires, Argentina</td>
</tr>
<tr>
<td>32</td>
<td>Chile</td>
<td>Office</td>
<td>Santiago, Chile</td>
</tr>
<tr>
<td>33</td>
<td>Columbia</td>
<td>Office</td>
<td>Santa de Bogotá, Colombia</td>
</tr>
<tr>
<td>34</td>
<td>Brazil</td>
<td>Office</td>
<td>Sao Paulo, Brazil</td>
</tr>
<tr>
<td>35</td>
<td>Australia</td>
<td>Office</td>
<td>Gordon, Australia</td>
</tr>
<tr>
<td>36</td>
<td>China</td>
<td>Office</td>
<td>Beijing, China</td>
</tr>
<tr>
<td>37</td>
<td>China</td>
<td>Office</td>
<td>Shanghai, China</td>
</tr>
<tr>
<td>38</td>
<td>Hong Kong</td>
<td>Office</td>
<td>Taikoo Shing, Island East Hong Kong</td>
</tr>
<tr>
<td>39</td>
<td>India</td>
<td>Office</td>
<td>Bangalore, India</td>
</tr>
<tr>
<td>40</td>
<td>India – Clinical</td>
<td>Office</td>
<td>Bangalore, India</td>
</tr>
<tr>
<td>41</td>
<td>Japan</td>
<td>Office</td>
<td>Tokyo, Japan</td>
</tr>
<tr>
<td>42</td>
<td>Korea</td>
<td>Office</td>
<td>Seoul, Korea</td>
</tr>
<tr>
<td>43</td>
<td>Philippines</td>
<td>Office</td>
<td>Pasig City, Philippines</td>
</tr>
<tr>
<td>44</td>
<td>Malaysia</td>
<td>Office</td>
<td>Selangor, Malaysia</td>
</tr>
<tr>
<td>45</td>
<td>Singapore</td>
<td>Office</td>
<td>Singapore</td>
</tr>
<tr>
<td>46</td>
<td>Taiwan</td>
<td>Office</td>
<td>Taipei, Taiwan</td>
</tr>
<tr>
<td>47</td>
<td>Thailand</td>
<td>Office</td>
<td>Bangkok, Thailand</td>
</tr>
<tr>
<td>48</td>
<td>South Africa</td>
<td>Office</td>
<td>Johannesburg, South Africa</td>
</tr>
<tr>
<td>49</td>
<td>France</td>
<td>Office</td>
<td>Courbevoie, France</td>
</tr>
<tr>
<td>50</td>
<td>Germany</td>
<td>Office</td>
<td>Ettlingen, Germany</td>
</tr>
<tr>
<td>51</td>
<td>Ireland</td>
<td>Office</td>
<td>Dublin, Ireland</td>
</tr>
<tr>
<td>52</td>
<td>Italy</td>
<td>Office</td>
<td>Rome, Italy</td>
</tr>
<tr>
<td>53</td>
<td>Poland</td>
<td>Office</td>
<td>Warsaw, Poland</td>
</tr>
<tr>
<td>54</td>
<td>Russia</td>
<td>Office</td>
<td>Moscow, Russia</td>
</tr>
<tr>
<td>55</td>
<td>Spain</td>
<td>Office</td>
<td>Madrid, Spain</td>
</tr>
<tr>
<td>56</td>
<td>Sweden</td>
<td>Office</td>
<td>Upplands Vasby, Sweden</td>
</tr>
<tr>
<td>57</td>
<td>Turkey</td>
<td>Office</td>
<td>Istanbul, Turkey</td>
</tr>
<tr>
<td>58</td>
<td>UK Office</td>
<td>Office</td>
<td>Buckinghamshire, UK</td>
</tr>
<tr>
<td>59</td>
<td>Grovesport</td>
<td>Office</td>
<td>Grovesport, OH</td>
</tr>
<tr>
<td>60</td>
<td>Olive Branch</td>
<td>Distribution</td>
<td>Olive Branch, MS</td>
</tr>
<tr>
<td>61</td>
<td>Weston</td>
<td>Distribution</td>
<td>Weston, FL</td>
</tr>
<tr>
<td>62</td>
<td>Fleets</td>
<td>Distribution</td>
<td>Worldwide</td>
</tr>
</tbody>
</table>